4.01 USD
▲+0.05+1.01%
盘后 4.04 +1.76%
2026-08-03
市值
$225.38M
市盈率
—
EPS
-1.35
股息率
—
52 周区间
2.97 – 7.82
成交量
425.77K
Beta
1.48
目标价
26.57
52W 低 2.9752W 高 7.82
价格走势
公司简介
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu...